OR WAIT 15 SECS
December 08, 2015.
Despite the currently high level of unmet need in the ovarian cancer therapeutic market, a strong pipeline of 462 diverse and innovative products in active development signals significant potential for alternatives to chemotherapy, according to GBI Research.
The company’s latest report states that as the market becomes more diverse, it will become less reliant on indiscriminate and highly cytotoxic chemotherapy regimens, which do not target specific proteins in aberrant pathways in ovarian cancer.
GBI analyst Joshua Libberton says that despite limited therapeutic options for ovarian cancer patients at the moment, almost 52% of ovarian cancer products in active development in the pipeline are considered to be first-in-class, as they have a molecular target not associated with any marketed products.
The high proportion of first-in-class innovation implies that the industry is pursuing novel approaches to treatment and reducing the focus on established therapies. Although innovation to date has been slow, greater disease understanding and awareness has created an environment in which it will thrive.
Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation